Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aarti Patel

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2012
The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonistsSimon Taylor, James R J Gray, Robert Willis, et al.
Implementation Science Communications|July 16, 2022
Intervention, individual, and contextual determinants to high adherence to structured family-centered rounds: a national multi-site mixed methods studyAndrew J Knighton, Ellen J Bass, Elease J McLaurin, et al.
Journal of Neurotrauma|August 18, 2022
Milnacipran Ameliorates Executive Function Impairments following Frontal Lobe Traumatic Brain Injury in Male Rats: A Multimodal Behavioral AssessmentTimothy J Craine, Nicholas S Race, Lindsay A Kutash, et al.
Frontiers in Neurology|October 18, 2019
Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation-A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial FibrillationDavid Z Rose, John N Meriwether, Michael G Fradley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2016
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry PerspectiveTonika Bohnert, Aarti Patel, Ian Templeton, et al.
Journal of Cardiac Failure|April 4, 2016
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary SpecialtyDaniel J Lenihan, Gregory Hartlage, Jeanne DeCara, et al.
JAMA Cardiology|June 17, 2026
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical TrialRonald G Crystal, Jonathan W Weinsaft, Stephen M Kaminsky, et al.
Clinical Pharmacology and Therapeutics|January 10, 2018
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium PerspectiveMohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2013
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteriaJoe Bentz, Michael P O'Connor, Dallas Bednarczyk, et al.
BMJ (Clinical Research Ed.)|December 7, 2018
Patient safety after implementation of a coproduced family centered communication programme: multicenter before and after intervention studyAlisa Khan, Nancy D Spector, Jennifer D Baird, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 10, 2012
The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonistsSimon Taylor, James R J Gray, Robert Willis, et al.
Implementation Science Communications|July 16, 2022
Intervention, individual, and contextual determinants to high adherence to structured family-centered rounds: a national multi-site mixed methods studyAndrew J Knighton, Ellen J Bass, Elease J McLaurin, et al.
Journal of Neurotrauma|August 18, 2022
Milnacipran Ameliorates Executive Function Impairments following Frontal Lobe Traumatic Brain Injury in Male Rats: A Multimodal Behavioral AssessmentTimothy J Craine, Nicholas S Race, Lindsay A Kutash, et al.
Frontiers in Neurology|October 18, 2019
Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation-A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial FibrillationDavid Z Rose, John N Meriwether, Michael G Fradley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2016
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry PerspectiveTonika Bohnert, Aarti Patel, Ian Templeton, et al.
Journal of Cardiac Failure|April 4, 2016
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary SpecialtyDaniel J Lenihan, Gregory Hartlage, Jeanne DeCara, et al.
JAMA Cardiology|June 17, 2026
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical TrialRonald G Crystal, Jonathan W Weinsaft, Stephen M Kaminsky, et al.
Clinical Pharmacology and Therapeutics|January 10, 2018
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium PerspectiveMohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 27, 2013
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteriaJoe Bentz, Michael P O'Connor, Dallas Bednarczyk, et al.
BMJ (Clinical Research Ed.)|December 7, 2018
Patient safety after implementation of a coproduced family centered communication programme: multicenter before and after intervention studyAlisa Khan, Nancy D Spector, Jennifer D Baird, et al.
Pageof 9